Observation on efficacy of tirofiban in patients with ischemic progressive stroke
10.16462/j.cnki.zhjbkz.2019.04.024
- Author:
Wen-shu NIU
1
;
Yang LIU
;
Yu-bin WANG
;
Qun NING
;
Zhi-yun LI
Author Information
1. Department of Clinical Neurology, 988th Hospital of People’s Liberation Army, Zhengzhou 450007, China
- Publication Type:Research Article
- Keywords:
Progressive stroke;
Tirofiban;
Curative effect
- From:
Chinese Journal of Disease Control & Prevention
2019;23(4):489-492
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of tirofiban in the treatment of ischemic progressive stroke. Methods 300 patients who met the diagnostic criteria of ischemic progressive stroke were divided into the control group and tirofiban group. Patients in the control group received treatment of PA2S regiment, i.e., a combination of aspirin, clopidogrel, probucol and atorvastatin. Patients in the tirofiban group received extra tirofiban on the basis of PA2S therapy. National institute of health stroke scale (NIHSS) score was evaluated on patients in both group before the therapy and 3 days, 1 month, 6 months after the therapy respectively. Results For the control group, the average NIHSS score was 11.3±4.2,11.5±4.4,8.8±4.1,6.1±4.1 before therapy and at 3 days, 1 month, 6 months after the therapy. And for the tirofiban group, the average NIHSS score was 11.4±3.9, 10.8±3.6, 7.4±3.2, 4.4±3.0 at the corresponding period respectively. There were statistical differences between the two groups in the period of 1 month and 6 months after treatment with P<0.001. Conclusions Tirofiban hydrochloride can improve the degree of neurological deficit and outcome in patients with ischemic progressive stroke.
